--- generated: '2026-08-04' method: generated source: apis.yml + lyciatx.com public pages (no /llms.txt is published by Lycia Therapeutics; https://lyciatx.com/llms.txt returned 404) --- # Lycia Therapeutics > Lycia Therapeutics is a privately held, research-stage biotechnology company in South > San Francisco, California, developing targeted protein degradation medicines on its > proprietary lysosomal targeting chimera (LYTAC) platform. LYTAC molecules bind a > disease-driving extracellular protein and shuttle it into the cell for destruction by > the lysosome, addressing circulating and membrane-bound proteins that small molecules > and antibodies have been unable to drug. Lycia publishes no public API, developer > portal, or machine-readable API artifacts. ## Company - Name: Lycia Therapeutics - Headquarters: 400 East Jamie Court, Suite 200, South San Francisco, CA 94080, USA - Sector: Biotechnology / therapeutics / drug discovery - Platform: LYTAC (lysosomal targeting chimera) targeted protein degradation - Scientific origin: the Stanford University laboratory of Carolyn Bertozzi, Ph.D., 2022 Nobel laureate in Chemistry - Chief Executive: Aetna Wun Trombley, Ph.D., President and CEO - Investors include: Versant Ventures, Redmile Group, Venrock, RTW, Blue Owl - Partnerships include: Eli Lilly and Company (LYTAC degrader discovery and development) - Ownership: private; secondary-market shares are listed on Forge Global ## Site - [Home](https://lyciatx.com/) - [Overview](https://lyciatx.com/about/overview/) - [About](https://lyciatx.com/about/) - [Team](https://lyciatx.com/about/team/) - [Investors](https://lyciatx.com/about/investors/) - [Partnering](https://lyciatx.com/about/partnering/) - [Technology](https://lyciatx.com/technology/) - [LYTAC platform](https://lyciatx.com/technology/lytac-platform/) - [Publications](https://lyciatx.com/technology/publications/) - [Pipeline](https://lyciatx.com/pipeline/) - [Programs](https://lyciatx.com/pipeline/programs/) - [Disease area focus](https://lyciatx.com/pipeline/disease-area-focus/) - [News](https://lyciatx.com/news/) - [News RSS](https://lyciatx.com/feed/) - [Careers](https://lyciatx.com/careers/) - [Contact](https://lyciatx.com/contact/) - [Terms of use](https://lyciatx.com/terms-of-use/) - [Privacy policy](https://lyciatx.com/privacy-policy/) ## APIs None. As of 2026-08-04 Lycia Therapeutics publishes no public API, no developer portal, and no machine-readable API contract. Probes of lyciatx.com for /openapi.json, /openapi.yaml, /swagger.json, /api-docs, /api, /graphql, /llms.txt and the full /.well-known/ discovery surface (security.txt, openid-configuration, oauth-authorization-server, oauth-protected-resource, api-catalog, ai-plugin.json, agent-card.json, agent.json) all returned HTTP 404. DNS lookups for api., developer., docs., dev., status. and trust. subdomains returned NXDOMAIN. ## API Evangelist profile - [apis.yml](https://raw.githubusercontent.com/api-evangelist/lycia-therapeutics/refs/heads/main/apis.yml) - [Domain security probe](https://raw.githubusercontent.com/api-evangelist/lycia-therapeutics/refs/heads/main/security/lycia-therapeutics-domain-security.yml) - [Well-known probe](https://raw.githubusercontent.com/api-evangelist/lycia-therapeutics/refs/heads/main/well-known/lycia-therapeutics-well-known.yml)